See Today's Golden Star Stocks 🔥 Free for 7 Days See Today's Golden Star Stocks 🔥 Free for 7 Days
NASDAQ:MDGL

Madrigal Pharmaceuticals Stock Predictions

etoro logo Buy MDGL
*Your capital is at risk
$512.88
+7.13 (+1.41%)
At Close: Jun 22, 2026
Forecast Earnings Financials Insider Trading Signals Historical Prices Predictions News Profile
Currently predicting for Wed, 24 Jun 2026
MDGL Live board
Community Bull/Bear
Target Next close

Join the MDGL prediction battle

Create a free account to see the full board, submit your call, compare with other predictors, and build a public record.

Create free account Log in

MDGL Prediction Chart

Unlock the prediction chart

Registered users can inspect target prices, community averages, and how calls develop across recent sessions.

Create free account Log in
Forecast Desk

3-Month Forecasts For MDGL

Forecasts map a 66-session price path from approved predictors. Log in or create a free account to view forecasts and request one for this ticker.

Create free account Log in to view forecasts

MDGL Predictions History

Predictor Target Session Target Price Accuracy
Community predictor Next session USD target Record locked
Ranked predictor Previous session Bullish/Bearish Score locked

See the prediction record

Register to view community history, predictor profiles, accuracy, scores, and your own prediction trail for MDGL.

Create free account Log in
Click to get the best stock tips daily for free!
Forecast Desk

Request A 3-Month Forecast

Log in or create a free account to view and request 66-session forecasts for MDGL.
  • Price path
  • Approved predictor
  • 3-month horizon
Create Free Account Log In To View Forecasts
ABOUT MADRIGAL PHARMACEUTICALS, INC.
Madrigal Pharmaceuticals
Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor-ß agonist, which is in Phase III clinical trials for the treatment of non-alcoholic steatohepatitis. The company also develops MGL-3745,...
Read Full Profile Here
GOLDEN STAR
Ticker Change Signal Date
IDYA
$28.98
18.12% Jun 12
DHI
$146.71
6.29% Jun 10
PHM
$118.49
6.02% Jun 10
EAT
$140.46
17.09% Jun 05
E
ETD
$20.67
3.19% Jun 05
Unlock

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE